Stock OVID OVID THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Ovid Therapeutics Inc.

Equities

OVID

US6904691010

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-09 pm EDT 		5-day change 1st Jan Change
0.8299 USD -0.71% Intraday chart for Ovid Therapeutics Inc. +7.31% -74.23%
Jul. 09 Immunic Names President/COO, Chief Development Officer MT
Jul. 09 Immunic Names Jason Tardio as COO, Werner Gladdines as Chief Development Officer MT

Evolution of the average Target Price on Ovid Therapeutics Inc.

Price target over the last 5 years

History of analyst recommendation changes

45be38ec9b649c1aea61ba9575a7b8be.39GrtSAmnqJt8BimHtzaG0EaVDzeWJXJElnBmenB-3I.vYGZ-GxM5ssuyEzcWLeKKSlzYEafafSHJwGW9dCLrx6P5uTnRnPnwCvEdw~26c2e95ac384f6533d60d543f08ff775

Analyst Recommendations on Ovid Therapeutics Inc.

Oppenheimer Downgrades Ovid Therapeutics to Market Perform MT
B. Riley Adjusts Price Target on Ovid Therapeutics to $3 From $9, Maintains Buy Rating MT
BTIG Adjusts Price Target on Ovid Therapeutics to $5 From $11, Maintains Buy Rating MT
HC Wainwright Adjusts Price Target on Ovid Therapeutics to $3 From $9, Maintains Buy Rating MT
Citigroup Adjusts Price Target on Ovid Therapeutics to $1.20 From $3.50, Maintains Neutral Rating MT
Wedbush Lowers PT on Ovid Therapeutics to $4 From $8 After Soticlestat Missed Endpoints in Phase 3 Studies; Maintains Outperform Rating MT
B. Riley Securities Initiates Ovid Therapeutics With Buy Rating, $9 Price Target MT
HC Wainwright Starts Ovid Therapeutics With Buy Rating, $9 Price Target MT
BTIG Initiates Ovid Therapeutics With Buy Rating, Price Target is $11 MT
Oppenheimer Initiates Coverage on Ovid Therapeutics With Outperform Rating, $8 Price Target MT
JonesTrading Initiates Ovid Therapeutics at Buy With $6 Price Target MT
Citigroup Adjusts Ovid Therapeutics' Price Target to $2.40 from $4, Keeps Neutral Rating MT
OVID THERAPEUTICS : Citigroup Adjusts Ovid Therapeutics' Price Target to $4 from $4.50, Keeps Neutral Rating MT
OVID THERAPEUTICS : Cantor Fitzgerald Downgrades Ovid Therapeutics to Neutral from Overweight, Adjusts PT to $4 from $8 MT
OVID THERAPEUTICS : RBC Cuts Price Target on Ovid Therapeutics to $4 From $5, Maintains Rating at Sector Perform, Speculative Risk MT
OVID THERAPEUTICS : Ladenburg Thalmann Adjusts Price Target on Ovid Therapeutics to $7 From $21, Maintains Buy Rating MT
OVID THERAPEUTICS : RBC Capital Adjusts Ovid Therapeutics PT to $5 From $17, Maintains Outperform - Speculative Risk Rating MT
OVID THERAPEUTICS : Citigroup Downgrades Ovid Therapeutics to Neutral From Buy, Adjusts Price Target to $4 From $10 MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
0.8299 USD
Average target price
3.314 USD
Spread / Average Target
+299.36%
High Price Target
5 USD
Spread / Highest target
+502.48%
Low Price Target
1.2 USD
Spread / Lowest Target
+44.60%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Ovid Therapeutics Inc.

Oppenheimer
Citigroup
HC Wainwright
BTIG
B. Riley
Wedbush
JonesTrading Institutional Services
Cantor Fitzgerald

Ratings for Ovid Therapeutics Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. OVID Stock
  4. Consensus Ovid Therapeutics Inc.